Drug · DIN 02242986
OPTIMARK
VIALS
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since March 23, 2018; first marketed August 20, 2001.
- Drug Identification Number (DIN)
- 02242986
- Company (DIN owner)
- Liebel-Flarsheim Canada IncPointe-Claire, Quebec, Canada
- Schedule
- Ethical
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Gadoversetamide V08CA06
- Class
- Human
- Record last updated
- June 23, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| GADOVERSETAMIDE | 330.9 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 13, 2015: NOC 16523New Drug Submission (NDS) · Transfer of drug identification numbers
- November 22, 2012: NOC 13878New Drug Submission (NDS) · Manufacturer name change
- May 27, 2002: NOC 565New Drug Submission (NDS) · Manufacturer name change
- December 11, 2000: NOC 1182New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “optimark”. A notice may cover another product or only some lots: read it to see what it covers.
- OPTIMARK (gadoversetamide injection) – Association with Nephrogenic Systemic Fibrosis (NSF) in Patients with Renal Impairment – For the PublicJanuary 12, 2010 · Drugs · Product safety
- OPTIMARK (gadoversetamide injection) Association with Nephrogenic Systemic Fibrosis (NSF) in Patients with Renal Impairment - For Health ProfessionalsJanuary 12, 2010 · Drugs
Other DINs named OPTIMARK
- DIN 02393158 · Cancelled Pre Market
- DIN 02393166 · Cancelled Pre Market
- DIN 02393174 · Cancelled Pre Market
- DIN 02393182 · Cancelled Pre Market